Compare Summit Therapeutics Inc (SMMT) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Clear Secure Inc — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Clear Secure Inc trades at $43.42 (market cap $4.49B). The key difference: Summit Therapeutics Inc is far larger — about 3.1× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.32% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | YOU | |
|---|---|---|
Market Cap | $13.79B | $4.49B |
Sector | Health | Technology |
52-Week High | $26.38 | $62.36 |
52-Week Low | $12.43 | $29.61 |
Enterprise Value | $13.11B | $3.64B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Clear Secure (YOU) trades at $43.6, down 1.65% on the day, amid a bearish technical signal. The company shows strong fundamental momentum with 27% year-over-year revenue growth in Q2 2026 and expanding profitability, though valuation ratios like a P/E of 29.46 appear elevated. Recent news highlights a strategic partnership with CrowdStrike and the launch of corporate memberships, signaling growth initiatives beyond airports.
The outlook is mixed: robust earnings beats and membership growth support upside, but high valuation and insider selling pose risks. Analyst consensus is evenly split between Buy and Hold, reflecting cautious optimism. Key near-term catalysts include Q3 2026 earnings and the success of new enterprise offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
